Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Agreements reached under this partnership
Business alliance4587PeptiDream Inc.
Alliance partner旭化成セラピューティクス
Details of the alliance
- 1
The companies have advanced the discovery of cyclic peptides using PDPS®.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
About the partner
Business Description旭化成セラピューティクス focuses on disease areas including autoimmune diseases, serious infectious diseases, transplantation, kidney diseases and orthopedics, and is advancing the discovery of new drugs.
LocationChiyoda-ku, Tokyo
Impact on Business Performance
The impact has already been incorporated into the earnings forecast for the fiscal year ending December 2026, and there is no change to the earnings forecast.
Contract DateMarch 2016Alliance start date20 April 2026 (start of Phase 1 clinical trial)
| Item | Details |
|---|---|
| Name of alliance partner | 旭化成セラピューティクス |
| Alliance partner's business activities | 旭化成セラピューティクス focuses on disease areas including autoimmune diseases, serious infectious diseases, transplantation, kidney diseases and orthopedics, and is advancing the discovery of new drugs. |
| Alliance partner's location | Chiyoda-ku, Tokyo |
| Type of alliance | Business alliance |
| Details of the alliance | The companies have advanced the discovery of cyclic peptides using PDPS®. |
| Contract Date | March 2016 |
| Alliance start date | 20 April 2026 (start of Phase 1 clinical trial) |
| Impact on Business Performance | The impact has already been incorporated into the earnings forecast for the fiscal year ending December 2026, and there is no change to the earnings forecast. |
Items this document does not state (15)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The two companies have advanced their joint research using our proprietary drug discovery development platform system, PDPS®. In addition, the drug aligns with 旭化成セラピューティクス' research and development strategy.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.